NCI Definition: A benign or malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma). Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors. [1]

Solid neoplasms most frequently harbor alterations in TP53, KRAS, PIK3CA, APC, and CDKN2A [2].

Most Commonly Altered Genes in Solid Neoplasm

TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and PIK3CA Mutation are the most common alterations in solid neoplasm [2].

Top Alterations in Solid Neoplasm

Significant Genes in Solid Neoplasm

ABL1 +




NF1 +

Disease Details

Solid tumor, NOS, Solid Tumor
Pre-malignant Neoplasm, Digestive System Neoplasm, Cardiovascular Neoplasm, Cerebellopontine Angle Tumor, Thyroid Gland Neoplasm, Mixed Neoplasm, Salivary Gland Neoplasm, Connective and Soft Tissue Neoplasm, Giant Cell Neoplasm, Metastatic Neoplasm, Brain Meningioma, Respiratory System Neoplasm, Sensory System Neoplasm, Central Nervous System Neoplasm, Peritoneal Neoplasm, Head and Neck Neoplasm, Embryonal Neoplasm, Central Nervous System Primitive Neuroectodermal Neoplasm, Neuroepithelial, Perineurial, and Schwann Cell Neoplasm, Myeloma, Breast Neoplasm, Retroperitoneal Neoplasm, Skull Neoplasm, Germ Cell Tumor, Trophoblastic Neoplasm, Urinary System Neoplasm, Nervous System Neoplasm, Malignant Solid Tumor, Endocrine Neoplasm, Refractory Malignant Neoplasm, and Mesoblastic Nephroma


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.